Skip to main content

News Center

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

2022

November 24, 2022 
The impact of inaction - New publication reveals not all of Canada is on track to meet global hepatitis C elimination goal

November 16, 2022 
Canadian migraine sufferers have new treatment option - Health Canada approves UBRELVY® (ubrogepant tablet)

October 20, 2022
AbbVie’s SKYRIZI® (risankizumab) receives Health Canada approval as the first and only specific Interleukin-23 (IL-23) to treat moderately to severely active Crohn’s Disease in adults

October 13, 2022
For World Sight Day, new app available for Canadians living with glaucoma, the Silent Thief of Sight

September 27, 2022 
XEN® 63 Gel Implant available now for patients with primary open angle glaucoma where previous medical treatments have failed

July 20, 2022 
Health Canada approves AbbVie’s RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis

June 22, 2022 
MAVIRET® (glecaprevir/pibrentasvir) approved by Health Canada for pediatric patients with chronic hepatitis C

April 27, 2022 
Health Canada approves VRAYLAR® (cariprazine) for the treatment of bipolar l disorder and schizophrenia in adults 

March 17, 2022
AbbVie expands immunology portfolio in Canada as Health Canada approves SKYRIZI® (risankizumab) for the treatment of adults with active psoriatic arthritis

March 9, 2022 
Focusing on the silent thief of sight during World Glaucoma Week

February 24, 2022 
AbbVie announces provincial reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL) in Alberta, Saskatchewan, British Columbia, and Manitoba

February 15, 2022 

AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology patients

February 10, 2022 
AbbVie announces first provincial reimbursements for VENCLEXTA® (venetoclax) in combination with Azacitidine for acute myeloid leukemia patients

2021

2020

December 15, 2020 
Health Canada Approves VENCLEXTA® (venetoclax) in combination with azacitidine or low dose cytarabine for untreated Acute Myeloid Leukemia (AML)

November 10, 2020
Health Canada Approves MAVIRET® 8-Week Treatment Duration for Treatment-Naïve Patients with Genotype 3 Compensated Cirrhosis 

October 1, 2020
Public coverage of AbbVie’s SKYRIZI® for the treatment of Moderate to Severe Plaque Psoriasis is now available across additional jurisdictions

July 28, 2020
We can eliminate Hepatitis C in Canada by 2030 

June 23, 2020
COVID-19 is hurting chronic migraine care in Canada

June 17, 2020
Endometriosis: an invisible disease affecting half a million Canadians

May 5, 2020
AbbVie Receives Health Canada Approval for the Combination of VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia

March 11, 2020
AbbVie announces new formulary listings for SKYRIZI® in the treatment of moderate to severe plaque psoriasis

February 26, 2020
VENCLEXTA® with Rituximab, a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL), now reimbursed in British Columbia

February 13, 2020
AbbVie’s SKYRIZI™ Now Listed on the Nova Scotia Formulary for the Treatment of Moderate to Severe Plaque Psoriasis

February 6, 2020
AbbVie's SKYRIZI™ now publicly reimbursed in Ontario, Alberta, Saskatchewan and Quebec for the treatment of moderate to severe plaque psoriasis 

January 14, 2020
AbbVie’s MAVIRET® now listed on the Newfoundland and Labrador formulary

January 7, 2020
AbbVie receives Health Canada approval of RINVOQ® (upadacitinib), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis

2019

December 18, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL)

December 6, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis

October 23, 2019
AbbVie’s Suzanne Campbell recognized by peers

September 25, 2019
VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada

July 25, 2019
AbbVie is committed to the elimination of hepatitis C in Canada by 2030

June 25, 2019
AbbVie Receives Positive Recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia

June 10, 2019
AbbVie’s MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

June 6, 2019
AbbVie Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia

May 30, 2019
AbbVie’s MAVIRET™ now listed in New Brunswick

May 23, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)

May 21, 2019
AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis

April 18, 2019
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

April 11, 2019
AbbVie’s MAVIRET™ now reimbursed in Quebec

April 4, 2019
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™

March 22, 2019
British Columbia PharmaCare Lists AbbVie’s Hepatitis C Treatment MAVIRET™ on its Formulary

February 21, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET™

February 20, 2019
AbbVie’s HUMIRA® (Adalimumab) approved by Health Canada to treat pediatric patients with chronic non-infectious anterior

2018

2017